Sarepta Therapeutics (SRPT) Continues Run as Eteplirsen Sentiment Remains High

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. DAL
10. TMUS

Go back to Sarepta Therapeutics (SRPT) Continues Run as Eteplirsen Sentiment Remains High

Sarepta Therapeutics (SRPT) Riding High On Successful Drug

August 30, 2012 8:08 AM EDT

Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive, tear-jerking press.

Yesterday evening,... More

Sarepta Therapeutics (SRPT) Higher on Barron's Mention

August 27, 2012 9:05 AM EDT

Sarepta Therapeutics (Nasdaq: SRPT) continues its recent ramp following a positive piece in Barron's over the weekend highlighting the company's treatment for Duchenne muscular dystrophy.

While shares are up from $4 to $10 recently, analysts argue they could go as high as $26 as peak sales of... More